Exhibit 99.1

Orthodontix Announces Name Change to Protalix BioTherapeutics, Inc.

Carmiel, Israel, March 1, 2007 /PRNewswire/ -- Orthodontix, Inc. (OTC Bulletin
Board: PXBT - News; "Orthodontix") today announced that it has changed its name
to Protalix BioTherapeutics, Inc. The trading symbol for the Company's common
stock will change at the open of business on Thursday, March 1, 2007, to PXBT.

About Protalix BioTherapeutics, Inc.

Protalix's proprietary technology is based on its plant cell culture and
bioreactor system which provides an effective and scaleable cell system for
industrial production of recombinant biopharmaceuticals. Protalix has recently
announced that it has completed Phase I clinical studies for its enzyme therapy
for Gaucher Disease, under an FDA Investigational New Drug study. Pending FDA
approval, Protalix intends to pursue advanced clinical studies for its enzyme
therapy for Gaucher Disease and to advance additional recombinant
biopharmaceutical drug development programs.

         Contact:          David Aviezer, Ph.D.
                           +972-4-988-9488